Regenerative medicine products to assist in stem cell treatment

Latest News:

Osiris Therapeutics Reports First Quarter 2008 Financial Results (05/09/08)

Osiris and NuVasive Enter into Definitive Agreement for Osteocel® (05/08/08)

Osiris Receives Approval for Use of Prochymal™ Under FDA Expanded Access Treatment Program (05/07/08)

Osiris Announces First Quarter 2008 Financial Results Conference Call (05/06/08)

A leader for more than a decade

Osiris Therapeutics, Inc. has been working since 1992 to develop and commercialize cellular therapies based on stem cells isolated from readily available adult bone marrow. These stem cells offer the opportunity to provide revolutionary treatments for a number of different indications. Read More

	Active Clinical Programs Osiris Therapeutics has active clinical programs for GVHD, heart attacks, knee injuries, and Crohn's disease. Read More
	Emergency Preparedness Osiris and Genzyme Partner to Develop Medical Countermeasures for Nuclear and Radiological Threats. Prochymal for ARS Defense

Adult stem cell technologies:

Osiris is developing stem cell technology with the potential to change the practice of medicine.


© 2008 Osiris Therapeutics, Inc. 7015 Albert Einstein Drive · Columbia, MD · 21046 · p(443)545-1800 · f(443)545-1701 osiris@osiris.com	Legal Notice